1. bookVolume 25 (2017): Issue 2 (April 2017)
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

Rapid liquid chromatography tandem mass spectrometry determination of rivaroxaban levels in human plasma for therapeutic drug monitoring

Published Online: 28 Apr 2017
Page range: 145 - 155
Received: 06 Nov 2016
Accepted: 17 Jan 2017
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

A rapid, sensitive, high-throughput liquid chromatography coupled with tandem mass spectrometry method for the quantification of rivaroxaban from human plasma has been developed and validated. For the analytical separation a Zorbax SB-C18 column with isocratic flow of mobile phase composed of 0.2% formic acid in water and acetonitril (65:35, V/V) with a flow rate of 1 mL/min at a temperature of 45ºC was used. Detection of rivaroxaban was performed using positive electrospray ionization and MS/MS mode (sum of m/z 231.1; 289.2 and 318.2 from m/z 436.3). Plasma samples were prepared using single-step protein precipitation with methanol. Method validation was performed with regards to selectivity, linearity (r >0.9927), within-run and between-run precision (CV< 13.1 %) and accuracy (bias< 9.4 %) over a concentration range of 24.00 - 960.00 ng/mL plasma. Recovery was between 96.5 - 108.5% and the lower limit of quantification of rivaroxaban was 24.00 ng/mL. The developed method is simple, rapid, and selective, requires small plasma sample volumes, and was successfully applied for therapeutic drug monitoring of rivaroxaban in treated patients.

Keywords

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov; 3(11): e442. 2011-30.10.1371/journal.pmed.0030442166460117132052Search in Google Scholar

2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrium fibrillation. N Engl J Med. 2009 Sep;361(12):1139-51. DOI: 10.1056/NEJMoa090556110.1056/NEJMoa090556119717844Search in Google Scholar

3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrilation. N Engl J Med. 2011 Sep; 365(10):883-91. DOI: 10.1056/NEJMoa100963810.1056/NEJMoa100963821830957Search in Google Scholar

4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep; 365(11):981-92. DOI: 10.1056/NEJMoa110703910.1056/NEJMoa110703921870978Search in Google Scholar

5. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov; 369(22):2093-104. DOI: 10.1056/ NEJMoa131090710.1056/NEJMoa131090724251359Search in Google Scholar

6. Scridon A, Șerban RC. Laboratory monitoring - a turning point in the use of new oral anticoagulants. Ther Drug Monit. 2016 Feb; 38(1):12-21. DOI: 10.1097/ FTD.000000000000024710.1097/FTD.000000000000024726352868Search in Google Scholar

7. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost. 2013 Jan;11:756-60. DOI: 10.1111/jth.1214910.1111/jth.1214923347120Search in Google Scholar

8. Kuhn J, Gripp T, Flieder T, Dittrich M, Hendig D, Busse J, et al. UPLC-MRM mass spectrometry method for measurement of the coagulation inhibitors dabigatran and rivaroxaban in human plasma and its comparison with functional assays. PLoS ONE. 2015 Dec; 10(12):e0145478. DOI: 10.1371/journal.pone.014547810.1371/journal.pone.0145478468954626699714Search in Google Scholar

9. Korostelev M, Bihan K, Ferreol L, Tissot N, Hulot JS, Funck-Brentano C, et al. Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2014 Nov;100:230-5. DOI: 10.1016/j.jpba.2014.08.01110.1016/j.jpba.2014.08.01125173108Search in Google Scholar

10. Cheng YH, Chen WC, Chang SY. Rapid determination of rivaroxaban in human urine and serum using colloidal palladium surface-assisted laser desorption/ ionization mass spectrometry. Rapid Commun Mass Spectrom. 2015 Nov; 29(21):1977-83. DOI: 10.1002/ rcm.730810.1002/rcm.730826443396Search in Google Scholar

11. Rohde G. Determination of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Sep; 872(1-2):43-50. DOI: 10.1016/j. jchromb.2008.07.015Search in Google Scholar

12. Schellings MW, Boonen K, Schmitz EM, Jonkers F, van den Heuvel DJ, Besselaar A, et al. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery. Thromb Res. 2016 Mar; 139:128-34. DOI: 10.1016/j. thromres.2016.01.012Search in Google Scholar

13. Srinivas Reddy G, Prasad Reddy SLN, Shiva Kumar Reddy L. Development and validation of Hplc-Ms/Ms Method for Rivaroxaban quantitation in human plasma using solid phase extraction procedure. Orient J Chem. 2016 Dec; 32(2):1145-54. DOI: 10.13005/ojc/32024010.13005/ojc/320240Search in Google Scholar

14. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Veterinary Medicine (CVM). Guidance for Industry. Bioanalytical Method Validation. 2013 Sep; available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdfSearch in Google Scholar

15. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on bioanalytical method validation. 2011, Jul; available at http:// www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdfSearch in Google Scholar

16. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008 Jan; 47(1):47-59. DOI: 10.2165/00003088-200847010-0000510.2165/00003088-200847010-0000518076218Search in Google Scholar

17. EINSTEIN-PE Investigators, Bűller HR, Prins MH, Lensin AW, Decousus H, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr; 366(14):1287-97. DOI: 10.1056/NEJMoa111357210.1056/NEJMoa111357222449293Search in Google Scholar

18. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral direct factor Xa inhibitor. Nat Rev Drug Discov. 2011 Jan;10(1):61-75. DOI: 10.1038/nrd318510.1038/nrd318521164526Search in Google Scholar

19. Gnoth MJ, Buetehorn U, Muenster U, Schwartz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011 Jul;338(1):372-80. DOI: 10.1124/ jpet.111.18024010.1124/jpet.111.18024021515813Search in Google Scholar

20. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther. 2007 Jun; 45(6):335-44. DOI: 10.5414/CPP4533510.5414/CPP4533517595891Search in Google Scholar

21. Ten Cate H. New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J 2013 Jun; 11(1):8. DOI: 10.1186/1477-9560-11-8 10.1186/1477-9560-11-8371668523809888Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo